Expression of HIV-1 Gag and Env Genes Using the Vesicular Stomatitis Virus Vector System by Baek, Justine
Western University
Scholarship@Western
2015 Undergraduate Awards The Undergraduate Awards
2015
Expression of HIV-1 Gag and Env Genes Using the
Vesicular Stomatitis Virus Vector System
Justine Baek
Western University, justinembaek@gmail.com
Follow this and additional works at: https://ir.lib.uwo.ca/ungradawards_2015
Part of the Medical Sciences Commons
Recommended Citation
Baek, Justine, "Expression of HIV-1 Gag and Env Genes Using the Vesicular Stomatitis Virus Vector System" (2015). 2015
Undergraduate Awards. 19.
https://ir.lib.uwo.ca/ungradawards_2015/19
  
 
 
 
 
 
 
 
Expression of HIV-1 gag and env genes using the vesicular stomatitis 
virus vector system 
 
                                           
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Abstract 
 
Traditional vaccine methods have long been employed to control widespread infectious 
diseases, but so far, all commercially available vaccine strategies have been inadequate in efforts 
to develop an effective therapeutic HIV vaccine. However, recent advancements in 
immunological research have lead to the generation of novel vaccine strategies, one of which is 
the recombinant virus vaccine, a method of particular interest that has shown promise in the 
clearance of HIV infection within HIV-positive patients who have retained immunocompetence. 
This study examined the stability of the expression of HIV-1 genes, gag and env, through a 
recombinant virus vector, a recombinant vesicular stomatitis virus (VSV), a temperature-
sensitive mutant genetically modified to contain the select HIV-1 genes (VSVInd(GML)HIV-
1gag-env). For SDS-PAGE, incubation was at 31 °C and 37 °C, the permissible and semi-
permissible growth conditions respectively for VSVInd(GML) temperature-sensitive mutants. 
Western blot analysis was used to quantitate levels of protein expression of full VSV proteins, 
Gag and Env, using a primary rabbit antibody of anti-VSV anti-serum and a secondary anti-IgG 
from rabbit, a primary antibody of anti-p24 anti-serum and a secondary anti-IgG from rabbit, and 
a primary goat antibody of anti-gp120, and a secondary anti-IgG from goat. Results indicated 
that the VSVInd(GML) vector system allowed for high levels of expression of HIV-1 gag and env 
genes. It is known that the expression of these genes induces the production of major neutralizing 
antibodies and the stimulation of cytotoxic T lymphocytes, revealing the potential to use a 
genetically modified recombinant VSV as a universal vector for the development of recombinant 
virus vaccines. Specifically, the VSVInd(GML) mutant vector is thus an attractive candidate for 
the viral vector of a therapeutic HIV vaccine system. 
 3 
Key words: Recombinant virus vaccine/ vesicular stomatitis virus / HIV-1 gag gene / HIV-1 env 
gene/ HIV/AIDS 
 
 
Background and Rationale 
 
According to the World Health Organization report in 2013, HIV has infected over 70 
million people and 36 million have died from AIDS-related illnesses since 1981. Additional 
reports from United Nations AIDS disclosed that 2.3 million were newly infected in 2012, adding 
to a total of 35.3 million people diagnosed with HIV infection as of 2013. HIV/AIDS is a rising 
world epidemic and our search for a method to control the spread of this disease has presented 
one of the most challenging problems of the past three decades.  
Vaccines are one of the most effective methods of controlling infectious disease and 
thus a central focus for HIV treatment has been on efforts to develop an effective therapeutic 
vaccine that will clear HIV infection. There are three types of commercially available vaccine 
strategies that are used to prevent many different viral diseases. These include the live-attenuated 
virus vaccine, such as the measles and mumps vaccines, the killed whole-virus vaccine, which 
has been used to prevent influenza virus and hepatitis A virus infection, and subunit vaccines, 
such as human hepatitis B virus and human papilloma virus vaccines. However, these three 
conventional vaccine strategies have so far proved inadequate for use as therapeutic HIV vaccine 
systems, effectively demonstrating our limited and largely empirically-based knowledge of these 
technologies and our lack of a comprehensive understanding of the immunological principles 
underlying widespread infectious diseases such as HIV (Luo, Li, & Kang, 2003; Hanke, 2001; 
Nature, 2009). Recent advancements however, have resulted in the generation of novel vaccine 
strategies, one of which is the recombinant virus vaccine, a method that has shown to be 
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promising in clearance of HIV infection within HIV-positive patients who have retained 
immunocompetence. 
  
Recombinant virus vaccines depend on the use of a viral vector to carry genes of interest, 
such as HIV genes, and express them in the body to activate CD8 positive cytotoxic T 
lymphocytes (CTLs). Development of a therapeutic HIV vaccine to clear persistently infected 
cells centers around the stimulation of adaptive host immune responses, in particular, the 
induction of antibody-dependent cellular cytotoxicity and the activation of viral-specific CTLs 
to destroy and clear HIV-infected cells (Kang, Luo, Wainberg, & Li, 1999). In particular, CTL 
response is considered a major immune defense mechanism required for recovery from nearly 
all viral infections (Luo et al., 1998). It is not desirable to use live HIV for CTL activation, but 
through a recombinant virus vaccine, it is possible to express selected HIV genes, which will 
activate HIV-specific CTLs.  
The stimulation of HIV-specific CTLs also depends on the HIV genes chosen for 
expression through the recombinant viral vector. HIV is a retrovirus with a genome expressing 
three major structural proteins, Gag (capsid protein, matrix protein), Pol (reverse transcriptase, 
RNase H, Integrase, protease) and Env (gp120 and gp41) (Goff, 2006). Particularly relevant are 
HIV-1 gag and env genes of which can play critical roles in the induction of adaptive-host 
immune responses (Kang, Luo, Wainberg, & Li, 1999). Gag, group-specific antigen, facilitates 
viral assembly and maturation (Ono, Orenstein, & Freed, 2000). When gag is expressed without  
pol in recombinant virus-infected cells, the precursor Gag55 assembles virus-like particles 
(VLPs) that are non-infectious and mimic HIV virions (Luo, Li, Dales, &, Kang, 1994). Env, 
envelope, comprises the Gp120 and Gp41 glycoproteins present on the surface of HIV as a trimer 
(Wu et al., 2009). Env precursor protein, Gp160, is synthesized in the endoplasmic reticulum and 
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then transported to the Golgi where it is cleaved into Gp120 and Gp41 by cellular proteases. The 
surface protein, Gp120, attaches to the cellular receptors, CD4 and chemokine receptors, of 
susceptible cells to initiate infection. In a study performed by Luo et al. (1998), it was found that 
HIV-1 Gag particles carrying multiple T-cell epitopes of Gp120 induced strong CTL responses. 
In a related study, Kang et al., (1999) demonstrated that HIV-1 gag-env VLPs resulted in high 
CTL activity. HIV-1 gag and env genes have thus been identified as strong candidates for use in 
an HIV/AIDS vaccine system and are therefore the genes of interest for this experiment. 
In this study, the viral vector selected for HIV-1 gene expression was an attenuated 
recombinant vesicular stomatitis virus (VSV), a member of the Rhabdoviridae family. VSV 
infects cattle, horses, and swine and, in humans, infection results in asymptomatic or mild flu-
like symptoms such as fever and malaise (Wu, Kim, & Kang, 2009). VSV has a negative-sense 
RNA genome containing 11,161 nucleotides, which encode five major viral structural proteins, 
the nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein 
(G), and the large protein (L) (Wagner, 1987; Lyles & Rupprecht, 2006; An, Kim, Wu, & Kang, 
2013). 
VSV presents an attractive viral vector system due to its wide host range, rapid 
replication processes, and mild pathogenicity in humans (An et al., 2013). Kim and Kang (2007) 
found that mutations introduced into the M gene of VSV result in an attenuated virus that exhibits 
reduced inhibitory effects on host cell gene expression and results in significantly less cytopathic 
effects within infected cell lines, a finding allowing for the production of avirulent and 
temperature-sensitive VSV mutants. Most valuable is the existence of VSV in two serotypes; 
Indiana (VSVInd) and New Jersey (VSVNJ). Wu et al. (2009) found that both serotypes have the 
capacity to stably express foreign genes and exhibit no cross-neutralization, revealing the 
potential for use of both VSV serotypes in a prime and boost method of vaccine delivery. 
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In order for the recombinant VSV vector to be used for an effective therapeutic HIV 
vaccine, the VSV vector system must be capable of stably expressing the HIV genes carried, an 
issue appraised in this study. In this research, I evaluated the expression of HIV-1 gag and env 
genes by employing VSVInd(GML), an avirulent and temperature-sensitive mutant vector system. 
High levels of HIV-1 gag and env gene expression by VSVInd(GML) indicate the potential for 
use of this viral vector system to activate CTLs and therefore confer immunity against infection 
through a therapeutic HIV vaccine. In this study, I describe the construction of the recombinant 
VSVInd(GML) vector, the recovery of the recombinant VSVInd(GML) mutant containing HIV-1 
gag and env genes by reverse genetics, and the quantitation of levels of protein expression in 
cells infected with the recombinant VSVInd(GML) containing gag and env genes.  
Hypothesis 
It was hypothesized that the recombinant VSVInd(GML) vector would successfully 
express HIV-1 gag and env genes based on the reputation of the recombinant VSV as a tolerant 
viral vector that has already been identified as having the acute ability to effectively express a 
range of foreign genes, such as those of Marburg and Ebola viruses (Mire et al., 2012). 
Quantitating the expression levels of HIV-1 Gag and Env proteins through the VSVInd(GML) 
vector system will indicate the potential for application of a recombinant VSV mutant as a major 
player in prospective therapeutic HIV vaccine development. 
 
 
 
Experimental Methods 
(1) Plasmid Construction 
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The recombinant VSVInd(GML)HIV-1gag-env vector was provided for this experiment; 
independent construction of the vector was not performed. However, the method of recombinant 
vector construction needs to be briefly addressed for clear understanding of the results. 
VSVInd(GML), an avirulent and temperature-sensitive mutant, was produced in the Kang 
Laboratory through the introduction of mutations at G21E, M51R, and L111A. Fusion of HIV-1 
gag and env genes created a gag-env hybrid gene. The gag gene insert also contained 171 
nucleotides that coded for T cell epitopes. The HIV-1 gag-env hybrid gene was inserted into the 
VSVInd(GML) genome between G and L genes of VSV by restriction enzyme Mlu1.  
 
(2) Cell culturing 
Baby Hamster Kidney21 (BHK21) cells were used to amplify recombinant 
VSVInd(GML)HIV-1gag-env. The cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 5.0% fetal bovine serum (Gibco BRL), antibiotics penicillin (100 μg/mL), 
streptomycin (100 μg/mL), and kanamycin (100 μg/mL), and L-Glutamine (2 mM). The cells 
were incubated in a 5.0% CO2 incubator at 37 °C for 17 hours and passaged when 100% 
confluent. 
 
Figure 1. Construction of recombinant VSVInd(GML)HIV-1gag-env; insertion of HIV-1 gag-env hybrid gene 
into VSVInd(GML) mutant genome by restriction enzyme Mlu1. TCE (T cell epitopes from gp41, gp120, and 
Nef) was attached to the C-terminus of Gag protein. The env gene contains the honeybee melittin signal 
peptide gene. The total gag-env gene insert is approximately 4,300 nucleotides. 
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(3) Transformation of E. coli DH5α 
Competent Cell Preparation 
E. coli DH5α colonies were streaked on a SOB agar media without antibiotics and 
incubated overnight at 37 °C. Five isolated colonies were transferred into 100 mL of SOB liquid 
media without antibiotics and grown using a shaking incubator set to 210 rpm at 37 °C. Cells 
were recovered by centrifugation at 4500 rpm at 4 °C for 10 minutes. 
 
Transformation 
E. coli DH5α cultures were first transformed with the plasmids N, P, L, and 
VSVInd(GML)HIV-1gag-env according to the Molecular Cloning Manual (Sambrook & Russell, 
2001). Plasmids diluted to 1 ng/μL were added into individual 200 μL aliquots of competent 
cells. A heat shock of 42 °C was then administered. Cells were shaken at 210 rpm and incubated 
at 37 °C for 1 hour. 200 μL of the transformed cells were spread onto lysogeny broth (LB) agar 
media with antibiotics and incubated at 37 °C. 
 
(4) DNA extraction by maxi-preparation 
E. coli DH5α colonies transformed with plasmids N, P, L, and VSVInd(GML)HIV-1gag-
env were screened for successful recombination. Positive clones were confirmed using restriction 
enzyme mapping with digestion by enzyme, Mlu1. Three transformed colonies for each plasmid 
were subcultured individually in 2 mL of LB with ampicillin and shaken at 210 rpm at 37 °C for 
17 hours. The subcultures were recovered by centrifugation at 5000 rpm at 4 °C for 10 minutes. 
The plasmid DNAs were purified and amplified to large quantities by the MAXIprep protocol 
(Sambrook & Russell, 2001) using Solution I [50 mM glucose, 25 mM Tris HCl (pH 8.0), 10 
mM EDTA (pH 8.0) with the addition of lysozyme [1 mg/1 mL], Solution II [1% SDS, 0.2 M 
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NaOH], and Solution III [7.5 M ammonium acetate]. DNA gel electrophoresis was performed to 
run extracted plasmid DNA alongside control plasmid DNA to verify successful extraction from 
bacterial cultures. 
 
(5) Recovery of VSVInd(GML)HIV-1gag-env by reverse genetics  
Transfection was performed using BHKT7 cells and Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s specifications in order to recover the recombinant 
VSVInd(GML)HIV-1gag-env by the VSV recovery protocol (Kim & Kang, 2007). Confluent 
BHKT7 cells were transfected with 19.4 μg of the plasmid containing VSVInd(GML)HIV-1gag-
env and co-transfected with 10 μg of pKS-HP, 10 μg of pKS-HN, and 5 μg of pKS-HL plasmid 
DNA. VSV-specific RNA polymerase was expressed through transcription of N, P and L plasmid 
DNA by T7 RNA polymerase and N, P, and L mRNAs were translated by Internal Ribosome 
Entry Sites (IRES). VSVInd(GML)HIV-1gag-env was transcribed and replicated by VSV-specific 
RNA polymerase (N, P, L), trimmed by HDV ribozyme, and assembled as the recombinant virus. 
Incubation was at 31 °C in a 5% CO2 incubator because the recombinant VSVInd(GML)HIV-
1gag-env is a temperature-sensitive mutant. The culture media was harvested when 80% of cells 
showed cytopathic effects (CPE), observed 96 hours post-transfection.  
 
 
 
(6) Purification and determination of viral titer by plaque assay 
Recovered virus, VSVInd(GML)HIV-1gag-env, was purified by three times plaque 
picking on BHK21 cells. The viral titer was then determined by a plaque assay in order to 
administer an infection at multiplicity of infection (MOI) of 0.1 to propagate the recovered 
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VSVInd(GML)HIV-1gag-env and attain a viral stock. Recovered VSVInd(GML)HIV-1gag-env 
was first diluted 10-4, 10-5 and 10-6 times. A 6-well plate of confluent Vero cells was inoculated 
with 100 μL of each dilution and incubated at 37 °C for 17 hours. The resulting plaque numbers 
were counted and determined the virus titer. Confluent BHK21 cells were infected at an MOI of 
0.1 with serum-free DMEM for propagation to attain a viral stock. A second plaque assay titration 
was performed repeating the same procedure in order to determine the viral titer of the viral stock 
for infection at an MOI of 6 to prepare the cell lysate for SDS-PAGE and Western blot analysis. 
 
(7) SDS-PAGE and Western blot analysis 
Infections at an MOI of 6 of confluent BHK21 cells were performed with 
VSVInd(GML)HIV-1gag-env and VSVInd(GML) without an insert as a negative control. 
Incubation was at 31 °C and 37 °C, the permissible and semi-permissible growth conditions for 
VSVInd(GML) temperature-sensitive mutants. The protein in the cell lysate obtained from these 
infections was quantitated by UV spectrophotometry. The infected cell lysates were used to 
perform an SDS-PAGE followed by Western blot analysis. Blotting was performed using TBS-
T buffer (0.1% Tween). Detection during Western blotting was performed to quantitate the 
expression of VSV proteins, Gag, and Env consecutively. For detection of VSV protein 
expression, a primary rabbit antibody of anti-VSV anti-serum was used with a secondary anti-
IgG from rabbit. Detection of Gag expression was performed with a primary rabbit antibody, 
anti-p24 anti-serum, and a secondary anti-IgG from rabbit. Detection of Env was then performed 
with primary goat antibody, anti-gp120, and a secondary anti-IgG from goat.  
 
Results 
(1) Gel electrophoresis of extracted DNA by maxi-preparation 
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DNA gel electrophoresis was used to verify successful extraction of each plasmid. DNA 
gel electrophoresis was performed with DNA plasmids N, P, and L (Fig. 1) and the recombinant 
vector, VSVInd(GML)HIV-1gag-env (Fig. 2). Samples of extracted DNA plasmids were 
electrophoresed alongside corresponding stock control plasmids. Electrophoresis results showed 
that the fragment sizes of extracted plasmids with marker plasmids were identical, indicating the 
successful extraction of these plasmids from bacterial cultures. 
 
 
 
 
 
 
 
 
 
 
(2) Recovery of VSVInd(GML)HIV-1gag-env 
by reverse genetics  
Bacteriophage T7 RNA polymerase is constitutively expressed in BHKT7 cells and this 
RNA polymerase transcribes the transfected pVSVInd(GML)HIV-1gag-env cDNA genome and 
co-transfected N, P and L plasmids. An Internal Ribosome Entry Site (IRES) allowed translation 
of VSV N, P, and L proteins, the VSV-specific RNA polymerase. After initial transcription of 
the recombinant VSVInd(GML)HIV-1gag-env genome by T7 RNA polymerase, it was replicated 
and transcribed by VSV-specific RNA polymerase (N, P, and L proteins) and the recombinant 
Figure 3. DNA gel electrophoresis of 
control stock and extracted plasmid DNA 
of VSVInd(GML)HIV-1gag-env; lane 1- 
control; lane 2- extracted. 
Figure 2. DNA gel electrophoresis of control stock 
and extracted plasmid DNA of N, P, and L. 
kbp 
kbp 
16.0 
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VSVInd(GML)HIV-1gag-env was assembled and released as a recombinant virus. Culture media 
containing the recombinant virus was harvested after observation of CPE in 80% of transfected 
cells 96 hrs post-transfection.  
 
 
 
 
 
 
 
 
 
 
 
(3) Determination of viral titer 
The recombinant virus was propagated by infection at an MOI of 0.1. The viral titer of 
the recombinant virus was determined by plaque assay on Vero cells. This procedure was 
repeated to determine the viral titer of the amplified recombinant virus for a second infection of 
BHK21 cells at MOI of 6. Resulting plaques and calculations for the determination of the viral 
titer for the recovered virus and the viral stock are shown in Table 1. 
Table 1 
 
Determination of Viral Titer of VSVInd(GML)-HIV-1gag-env 
Figure 4. Recovery of VSVInd(GML)HIV-1gag-env using Reverse Genetics. BHKT7 cells are 
transfected with pVSVInd(GML)HIV-1gag-env and co-transfected with pN, pP, and pL. Culture 
media was harvested from transfected cells after observation of 80% CPE (Buchholz, Fink & 
Conzelmann, 1999). 
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For Infection Counted 
Plaques 
Averaged 
Plaques 
Account for  
Dilution Factor 
Account for  
Inoculation (100 μL) 
Virus Titer 
(pfu/mL) 
 
MOI 0.1 
 
22, 23 
 
22.5 
 
×106 
 
 
×10 
 
2.25 × 108 
 
MOI 6 22, 33 27.5 ×106 ×10 2.75 × 108 
 
(4) Quantitation of levels of protein expression by SDS-PAGE and Western blot analysis 
Virus-infected cell lysates were analyzed by SDS-PAGE followed by Western blot 
analysis for the quantitation of levels of viral protein expression. This was performed using cell 
lysate prepared from infections with VSVInd(GML) containing no insert and VSVInd(GML)HIV-
1gag-env at 31 °C and 37 °C. Expression of HIV-1 Gag and Env proteins are marked by arrows 
in the following figures.  
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Discussion 
Figure 5. Expression of full VSVInd protein; 
lane 1- VSVInd no inserts, lane 2- 
VSVInd(GML)HIV-1gag-env 
Figure 6. Expression of HIV-1 Gag55; lane 1- 
VSVInd no inserts, lane 2- VSVInd(GML)HIV-
1gag-env 
Figure 7. Expression of HIV-1 Env (gp160); 
lane 1- VSVInd no inserts, lane 2- 
VSVInd(GML)HIV-1 gag-env 
Env (gp160) 
MW marker MW marker 
MW marker 
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Results indicate that the VSVInd(GML) vector system allowed for high levels of 
expression of HIV-1 gag and env genes. This finding reveals the potential to use a genetically 
modified recombinant VSV as a universal vector for the development of recombinant virus 
vaccines. The VSVInd(GML) mutant vector is thus an attractive candidate for the viral vector of 
a therapeutic HIV vaccine. These major findings are concluded through the following analysis 
of results: 
(1) Gel electrophoresis of DNA extracted through maxi-preparation confirmed successful 
extraction of pN, pP, pL, and VSVInd(GML)HIV-1gag-env from E. coli DH5α bacterial cultures. 
This was established from the results of gel electrophoresis shown in Figures 1 and 2, which 
depict identical fragment sizes for corresponding control and experimental plasmids run for each 
DNA isolate. 
(2) Recovery of VSVInd(GML)HIV-1gag-env using reverse genetics was accomplished with the 
harvest of culture media containing the recombinant virus after observation of CPE in 80% of 
transfected BHKT7 cells 96 hours post-transfection. Longer incubation time was required before 
infected cells exhibited CPE because VSVInd(GML) is an attenuated, avirulent mutant. 
(3) The results acquired from SDS-page and Western blot analysis indicated that VSVInd(GML) 
containing no insert and VSVInd(GML)HIV-1gag-env both showed the same levels of VSVInd 
protein expression at both permissive and semi-permissive temperatures, indicating that the 
stability of VSVInd was not compromised by HIV-1 gene insertion. The high levels of expression 
of both HIV-1 Gag and Env proteins by VSVInd(GML)HIV-1gag-env demonstrates that the 
VSVInd(GML) vector system is capable of stably expressing HIV genes gag and env, revealing 
the potential of VSVInd(GML) for use in a recombinant virus vaccine system.  
In summary of the experimental procedures performed, the major steps of this study 
comprised of vector construction with the insertion of an HIV-1 gag-env hybrid gene into the 
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VSVInd(GML)  genome, recovery of the recombinant virus by reverse genetics, and quantitation 
of levels of protein expression in infected cell-lines. The procedures performed were successful 
for obtaining the results needed to make conclusive evaluations of the VSVInd(GML) vector 
system. 
Similar results were shown in a study performed by Rose et al. (2000), who 
demonstrated the use of a recombinant VSV to effectively express HIV-1 genes through the 
sequential boosting of mice with recombinant VSV vectors encoding the HIV-1 Env protein. 
Results revealed a great increase in the production of HIV-specific neutralizing antibodies. CTL 
activation was not evaluated, but, a parallel study performed by Egan et al. (2004), demonstrated 
a significant increase in CTL response in macaques with vaccination using recombinant VSV-
based vectors expressing HIV-1 Env and simian-human immunodeficiency virus (SIV) Gag 
proteins. The observations presented by these studies determined the same conclusions discussed, 
identifying the ability of a recombinant VSV vector to express and process HIV-1 Gag and Env 
proteins. Such results have also been expanded upon in a study performed by Wu, Kim, & Kang 
(2009) who, in addition to highlighting the capability of the VSVInd(GML) vector system to 
express HIV-1 genes, found that its counterpart, the VSV New Jersey serotype, also possesses 
the ability to express HIV-1 gene, env (gp160), a finding that can be used in conjunction with 
this study’s results to conclude the capability of both serotypes of VSV to express inserted HIV-
1 genes. This suggests the potential of employing both VSV vector systems in the development 
of priming and boosting vaccines, using the VSV expression system to activate CD8 positive 
CTLs.  
 To conclude, VSVInd(GML)HIV-1gag-env is capable of expressing HIV-1 Gag and 
Env proteins at both permissive and semi-permissive temperatures. For application to a 
recombinant virus vaccine system, it is desirable to develop a RNA virus vector capable of 
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accommodating large foreign genes, allowing high levels of foreign gene expression. Therefore, 
these positive results reveal the potential use of VSVInd(GML) as an efficient viral vector system 
for a candidate therapeutic HIV vaccine to clear chronic HIV infection. This presents optimistic 
prospects for the development of a vaccine system that can substitute the high prices of anti-
retrovirus therapeutic drugs with a cost-effective immunotherapy that will help clear infection 
from millions of people diagnosed with HIV. 
 
Future Work 
Future research currently focuses on the application of recombinant virus vaccine 
systems for the treatment of other infectious diseases such as the hepatitis C virus and even 
bacterial diseases such as tuberculosis. The results from this experiment suggest that additional 
projected studies of protective immune responses in animal models and the evaluation of the 
side-effects of recombinant virus vaccine systems may be beneficial to expand our knowledge of 
the immunological mechanisms underlying viral infections so that it may be possible to develop 
more effective and economic anti-viral therapies. 
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